After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope. Years before Onyx entered my life, I lost my beloved dog ...

Expanded timing includes annual MRD testing during maintenance and after subsequent therapy lines, including following CAR-T, to enable serial assessment rather than single timepoint interpretation.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope.

Local transplant availability reduced patient travel burden and preserved continuity for long-term oncology relationships, reinforcing the program’s mission around access and community-based care.

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant ...

A dedicated movement space can serve as a survivorship anchor, reinforcing identity, agency, and continuity through training ...

In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology ...

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope.

Trials are designed with patient safety in mind while helping researchers determine whether a new treatment is safe and effective. Some cancer trials do use a placebo, an inactive pill, but patients ...